OBJECTIVE: Heart failure treatment in general practice is not concordant with guideline recommendations. Insight into the key determinants at different levels is needed in order to improve care. The aim was to assess the influence of physician, organisational and patient characteristics on the treatment of chronic heart failure with angiotensin converting enzyme (ACE) inhibitors in primary care. METHODS: Physician and organisational data were collected by means of a questionnaire. Patient and treatment data were extracted from electronic medical records. Multilevel analysis was used to assess the effect of physician, organisational and patient factors on the treatment with ACE inhibitors in terms of prescription rate and dosage. RESULTS: Data from 735 randomly selected heart failure patients were extracted from the medical records of 95 general practitioners (GPs). Patients who visited a cardiologist or an outpatient heart failure clinic were more likely to receive an ACE inhibitor. In addition, relatively young patients, male patients and patients already using a diuretic were more likely to receive an ACE inhibitor. Furthermore, male patients and patients with concomitant hypertension were more likely to receive a higher dose of ACE inhibitor. GP characteristics did not determine whether CHF patients received ACE inhibitor treatment. CONCLUSION: The differences in ACE inhibitor prescribing seem to be linked more to patient than physician characteristics. Interventions to improve the quality of care should therefore focus on the treatment of specific patient groups. Specialised care, particularly through outpatient clinics, could lead to improvement in the use of ACE inhibitors.
OBJECTIVE:Heart failure treatment in general practice is not concordant with guideline recommendations. Insight into the key determinants at different levels is needed in order to improve care. The aim was to assess the influence of physician, organisational and patient characteristics on the treatment of chronic heart failure with angiotensin converting enzyme (ACE) inhibitors in primary care. METHODS: Physician and organisational data were collected by means of a questionnaire. Patient and treatment data were extracted from electronic medical records. Multilevel analysis was used to assess the effect of physician, organisational and patient factors on the treatment with ACE inhibitors in terms of prescription rate and dosage. RESULTS: Data from 735 randomly selected heart failurepatients were extracted from the medical records of 95 general practitioners (GPs). Patients who visited a cardiologist or an outpatientheart failure clinic were more likely to receive an ACE inhibitor. In addition, relatively young patients, male patients and patients already using a diuretic were more likely to receive an ACE inhibitor. Furthermore, male patients and patients with concomitant hypertension were more likely to receive a higher dose of ACE inhibitor. GP characteristics did not determine whether CHFpatients received ACE inhibitor treatment. CONCLUSION: The differences in ACE inhibitor prescribing seem to be linked more to patient than physician characteristics. Interventions to improve the quality of care should therefore focus on the treatment of specific patient groups. Specialised care, particularly through outpatient clinics, could lead to improvement in the use of ACE inhibitors.
Authors: Lisa G Pont; Wiek H van Gilst; Dirk J A Lok; Hans J A Kragten; Flora M Haaijer-Ruskamp Journal: Eur J Heart Fail Date: 2003-03 Impact factor: 15.534
Authors: M Komajda; F Follath; K Swedberg; J Cleland; J C Aguilar; A Cohen-Solal; R Dietz; A Gavazzi; W H Van Gilst; R Hobbs; J Korewicki; H C Madeira; V S Moiseyev; I Preda; J Widimsky; N Freemantle; J Eastaugh; J Mason Journal: Eur Heart J Date: 2003-03 Impact factor: 29.983
Authors: Carel F Schaars; Petra Denig; Willeke N Kasje; Roy E Stewart; Bruce H R Wolffenbuttel; Flora M Haaijer-Ruskamp Journal: Diabetes Care Date: 2004-01 Impact factor: 19.112
Authors: Daniel Carlzon; Lena Gustafsson; Anna L Eriksson; Karin Rignér; Anders Sundström; Susanna M Wallerstedt Journal: BMC Clin Pharmacol Date: 2010-02-15
Authors: Lise Juul; Annelli Sandbaek; Anders Foldspang; Morten Frydenberg; Knut Borch-Johnsen; Torsten Lauritzen Journal: Scand J Prim Health Care Date: 2009 Impact factor: 2.581
Authors: Frank Peters-Klimm; Gunter Laux; Stephen Campbell; Thomas Müller-Tasch; Nicole Lossnitzer; Jobst-Hendrik Schultz; Andrew Remppis; Jana Jünger; Christoph Nikendei Journal: PLoS One Date: 2012-02-21 Impact factor: 3.240
Authors: Sana Shoukat; Saqib A Gowani; Ather M Taqui; Rameez Ul Hassan; Zain A Bhutta; Anum I Malik; Sajjad A Sherjeel; Quratulanne Sheheryar; Sajid H Dhakam Journal: BMC Cardiovasc Disord Date: 2011-11-17 Impact factor: 2.298
Authors: Rizwan Zafar; Muhammad Haris; Salman Assad; Muhammad Usman Shabbir; Haider Ghazanfar; Sarah A Malik; Tehreem Khalid; Ali H Abbas; Asad A Saleem Journal: Cureus Date: 2016-08-08
Authors: Jozette J C Stienen; Rosella P M G Hermens; Lianne Wennekes; Saskia A M van de Schans; Richard W M van der Maazen; Helena M Dekker; Janine Liefers; Johan H J M van Krieken; Nicole M A Blijlevens; Petronella B Ottevanger Journal: BMC Cancer Date: 2015-08-08 Impact factor: 4.430